ArticleTransfusion2020
Transfusion-associated adverse events and implementation of blood safety measures - findings from the 2017 National Blood Collection and Utilization Survey.
Article in Transfusion, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.Advances in therapy · 2022Pooled it
- N-Acetylcysteine Attenuates Oxidative Stress and Preserves Red Blood Cell Quality During Whole Blood Storage.Antioxidants (Basel, Switzerland) · 2026Article
- CD71Scandinavian journal of immunology · 2026Article
- History matters: Preventing severe allergic transfusion reactions.American journal of clinical pathology · 2025Article
- The Impact of Young and/or Exercised Blood Plasma Transfusions in Individuals With Neurodegenerative Conditions: Protocol for a Scoping Review.JMIR research protocols · 2025Article
- Supplemental findings of the 2021 National Blood Collection and Utilization Survey.Transfusion · 2023Article
- Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients.Pathogens (Basel, Switzerland) · 2023Review
- Racial differences in red blood cell transfusion in hospitalized patients with anemia.Transfusion · 2022Article
- Analyzing real world data of blood transfusion adverse events: Opportunities and challenges.Transfusion · 2022Article
- Expanded validation of the effect and quality of a pathogen inactivation system based on riboflavin photochemistry on platelet bacterial contamination.Annals of translational medicine · 2021Article
- Supplemental findings of the 2019 National Blood Collection and Utilization Survey.Transfusion · 2021Article
- Transfusion-Associated Hyperkalemic Cardiac Arrest in Neonatal, Infant, and Pediatric Patients.Frontiers in pediatrics · 2021Review
- Transfusion Reactions in Pediatric Patients: An Analysis of 5 Years of Hemovigilance Data From a National Center for Children's Health in China.Frontiers in pediatrics · 2021Article
- The use of premedications for platelet transfusions in pediatric patients.Hematology. American Society of Hematology. Education Program · 2020Review
- Potential Consequences of the Red Blood Cell Storage Lesion on Cardiac Electrophysiology.Journal of the American Heart Association · 2020Article
- Supplemental findings of the 2017 National Blood Collection and Utilization Survey.Transfusion · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSerious transfusion-associated adverse events are rare in the United States. To enhance blood safety, various measures have been developed. With use of data from the 2017 National Blood Collection and Utilization Survey (NBCUS), we describe the rate of transfusion-associated adverse events and the implementation of specific blood safety measures. STUDY DESIGN AND
methodsData from the 2017 NBCUS were used with comparison to already published estimates from 2015. Survey weighting and imputation were used to obtain national estimates of transfusion-associated adverse events, and the number of units treated with pathogen reduction technology (PRT), screened for Babesia, and leukoreduced.
resultsThe rate of transfusion-associated adverse events requiring any diagnostic or therapeutic interventions was stable (275 reactions per 100,000 transfusions in 2015 and 282 reactions per 100,000 transfusions in 2017). In 2017 among US blood collection centers, 16 of 141 (11.3%) reported screening units for Babesia and 28 of 144 (19.4%) reported PRT implementation; 138 of 2279 (6.1%) hospitals reported transfusing PRT-treated platelets. In 2017, 134 of 2336 (5.7%) hospitals reported performing secondary bacterial testing of platelets (50,922 culture-based and 63,220 rapid immunoassay tests); in 2015, 71 of 1877 (3.8%) hospitals performed secondary testing (87,155 culture-based and 21,779 rapid immunoassay tests). Nearly all whole blood/red blood cell units and platelet units were leukoreduced.
conclusionsBesides leukoreduction, implementation of most blood safety measures reported in this study remains low. Nationally, hospitals might be shifting from culture-based secondary bacterial testing to rapid immunoassays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.